
|Articles|April 1, 2004
- BioPharm International-04-01-2004
- Volume 17
- Issue 4
Site Expansion - Regional Round-Up: North Carolina
Regional Round-Up: North Carolina
Advertisement
Key cities and populations
Charlotte: 581,676; Raleigh: 303,567; Greensboro: 227,793; Durham: 198,688; Winston-Salem: 190,851; Fayetteville: 123,844
Largest Metropolitan Statistical Areas: Charlotte-Gastonia: 1,404,862; Greensboro-Winston Salem-High Point: 1,283,509;Raleigh-Durham-Chapel Hill: 1,268,372
Targeted industries
According to the North Carolina Department of Commerce, targeted companies include those in industries traditionally considered "high tech," such as telecommunications and biotechnology, and companies that apply new and innovative technology to remain competitive in traditional industries, such as textiles and furniture (visit
Biopharm employment
Approximately 20,000 in biopharmaceuticals and pharmaceuticals
Academia affiliated with biopharm industry
Duke University; East Carolina University; University of North Carolina-Chapel Hill; Wake Forest University
Primary business strengths
R&D; contract biomanufacturing; clinical research and testing
Tax and other incentives
Various tax incentives and relocation inducements; tailored workforce training through the state's 54 community colleges
BioClusters
Research Triangle region of Raleigh, Durham, Chapel Hill, and the Research Triangle Park, 100-plus biotechnology companies and 75 contract research and testing companies:
State commitment to biopharm industry and future plans for its growth
The North Carolina Biotechnology Center — the world's first government-sponsored biotechnology initiative — is in its third decade of promoting biotechnology development in the state; Golden LEAF, a foundation set up by the state to invest tobacco settlement funds in economic development, has committed $60 million for a statewide network to train workers for jobs in biomanufacturing and pharmaceutical manufacturing; and in 2003, the state's General Assembly created a Life Sciences Revenue Bond Authority to help companies finance the construction of biomanufacturing plants in the state. A strategic plan for growing North Carolina's biotechnology industry was presented to Governor Mike Easley in January 2004. The plan, "New Jobs Across North Carolina," includes 54 recommendations aimed at improving research, business, and education statewide with emphasis on biomanufacturing and start-up companies (visit
State- and regional-level contacts
North Carolina Biotechnology Center
Articles in this issue
over 21 years ago
NASA's Cell Culture Unit Brings Space Station Research Down to Earthover 21 years ago
Using Macros and Spreadsheets in a Regulated Environmentover 21 years ago
Editorial—Sustainability for a Long-Distance Raceover 21 years ago
Roslin Institute, Edinburghover 21 years ago
Ardana: A Global Company Based in Edinburghover 21 years ago
Five Tips for Better Biotechnology Writingover 21 years ago
Quintiles in Edinburgh: An Ideal Environmentover 21 years ago
Site Expansion - Regional Round-Up: South Carolinaover 21 years ago
Finding a New Position in a Competitive Job MarketNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4